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Abstract
Macrophages are white blood cells that have important roles in phagocytosis and immune responses.
A series of recent papers reveals that nuclear receptors influence the precise pathway of macrophage
phenotype polarization and that these effects protect against insulin resistance and metabolic
syndrome, the most important group of diseases facing the industrialized world.
Introduction and context
Obesity and insulin resistance are often accompanied by
low-grade systemic inflammation, and these seemingly
disparate phenomena are linked by adipose tissue
macrophages (ATMs) [1]. Macrophages are derived
from circulating monocytes that migrate into target
tissues [2]. Histological analysis reveals striking macro-
phage infiltration into the white adipose tissue (WAT) of
obese and insulin-resistant individuals and this is
coupled to expression of inflammatory genes [3,4]. The
relationship between insulin resistance and macrophage-
mediated inflammation is causal and not simply
correlative. Mice with disruptions in genes that mediate
monocyte infiltration (for example, genes encoding the
chemokine MCP-1 and the chemokine receptor CCR2)
and the macrophage inflammatory response (for exam-
ple, genes encoding the cytokine TNFa, the TNF receptor,
the kinase JNK, and the NF-kB inhibitor kinase Ikkb)
improved metabolic profiles, and high doses of anti-
inflammatory salicylates improve insulin sensitivity in
humans [5].
Peroxisome proliferator-activated receptor gamma
(PPARg) is a nuclear receptor that is activated by fatty
acids, and recent discoveries have focused attention on
its role in the polarization of macrophage phenotype [6].
It is now known that macrophage phenotype varies
greatly in a manner that is influenced by local
microenvironment: classically activated M1 macro-
phages are recruited to sites of infection and tissue
damage, where they engulf debris and trigger adaptive
immune responses, whereas alternatively activated M2
macrophages limit local inflammatory responses and
promote tissue repair [7]. PPARg is best known for its
influence on adipocyte development and as the target for
insulin-sensitizing drugs, the thiazolidinediones [8].
However, PPARg also exerts a widespread influence on
macrophage biology [8–10]; PPARg activators repress
pro-inflammatory genes, stimulate transcriptional cas-
cades that promote cholesterol export from foam cells
(lipid-laden macrophages) in atherosclerotic plaque and
inhibit macrophage infiltration into WAT. In 2007, two
groups made the remarkable observation that PPARg is
required for M2 macrophage polarization [6,11]. Equally
surprisingly, PPARg-dependent M2 polarization protects
against insulin resistance and other aspects of metabolic
syndrome. Mice with macrophage-specific PPARg gene
disruptions exhibit increased obesity on high-fat diets
and many of the hallmarks of systemic insulin resistance,
including altered capacity for glucose uptake and
oxidative phosphorylation in skeletal muscle [6,12].
Major recent advances
How does disruption of the PPARg gene in macrophages
influence insulin resistance and obesity? Because M2
polarization inhibits local inflammatory responses, it
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-/- macrophages secrete inflam-
matory cytokines that alter adipocyte function (Figure 1).
Accordingly, Odegaard and colleagues find increased
expression of inflammatory markers in adipose tissue in
the macrophage-specific PPARg-knockout mice [6]. This
effect is coupled to suppression of multiple genes
involved in adipocyte function and insulin response,
and co-culture experiments confirm that PPARg
-/- macro-
phages produce secreted factors that limit insulin
sensitivity in adipocytes. Overall, changes in adipocyte
function are likely to alter secretion of multiple
adipocyte hormones that affect the systemic insulin
response. In addition, reduced fat storage in adipose
tissue depots will probably be coupled to increased
accumulation of lipids in liver, skeletal muscle and other
locations with known inhibitory effects on insulin
sensitivity in these tissues. PPARg-dependent M2 polar-
ization might also exert direct effects on other tissues:
Hevener and colleagues [12] find that hepatic insulin
sensitivity varies with the extent of PPARg
-/- macrophage
infiltration into liver.
Two recent studies have highlighted an equally impor-
tant role for another PPAR subtype (PPARg) in alter-
native macrophage activation and insulin resistance
[13,14]. PPARg is highly expressed in macrophages and
is implicated in transcriptional repression of atherogenic
inflammation [15–17]. It is also known that alternative
macrophage activation is associated with fatty acid
b-oxidation and oxidative metabolism [18]: classic
effects of PPARg. Both studies confirm that PPARg is
required for expression of M2-specific genes and show
that mice with macrophage-specific PPARg
-/- knockouts
develop systemic insulin resistance and hepatic steatosis.
Results are not in complete agreement; Odegaard et al.
[13] find that macrophage-specific PPARg knockouts
mainly affect hepatic insulin sensitivity via influences on
polarization of resident liver macrophages (Kupffer
cells), whereas Kang et al.[14] observe prominent effects
on ATMs, reductions in adipose tissue insulin sensitivity
and adipocyte lipolysis. These discrepancies may be
related to the nature of the mouse knockout model, but
it should be emphasized that they do not detract from
the main conclusion; PPARg protects against insulin
resistance via effects on M2 macrophage polarization.
The papers also point towards roles for cross-talk
between resident macrophages and host tissues in local
inflammation and development of insulin resistance
[13,14]. Kang et al. [14] find that adipocytes and
hepatocytes produce helper T-cell (Th2)-type cytokines
(IL-4 and IL-13) which prime macrophages along the
M2 pathway to limit local inflammatory response; in
fact, IL-4 enhances PPARg expression, directly linking
IL-4 signaling to the PPARg pathway. Both groups find
that PPARg
-/- macrophages secrete paracrine factors that
promote adipocyte and hepatocyte dysfunction in co-
culture experiments. These observations raise the inter-
esting possibility that alterations in resident macrophage
polarization lead to runaway derangements in tissue/
macrophage interactions in MSX. As macrophages
acquire pro-inflammatory characteristics they will alter
cytokine secretion in surrounding tissues to trigger
further inflammatory responses and production of
factors that inhibit local and systemic insulin responses.
Future directions
In summary, the fascinating implication of this series of
papers is that strategies that promote M2 macrophage
polarization will cure systemic insulin resistance and
prevent MSX. Much remains to be learned. There are
actually multiple M2 macrophage types with incomple-
tely defined functions [7]; it is not clear whether all M2
subtypes protect against insulin resistance and MSX. It is
also not clear that M2 macrophages are always beneficial,
as they are implicated in tumor inflammation and
fibrosis [1]. It is also likely that macrophage nuclear
receptors will be attractive targets for drugs that influence
macrophage polarization and insulin resistance; PPARg
and PPARg have proven beneficial effects and about half
of the members of the nuclear receptor gene family are
expressed in macrophages [19]. Dissecting the actions of
nuclear receptors in macrophage biology is likely to
become an even more fertile area of research in the next
few years.
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Monocytes that enter adipose tissue develop into adipose tissue macro-
phages (ATMs) that can be polarized in two ways: M2 macrophages respond
to local Th2 cytokines to limit the inflammatory response, whereas M1
macrophages respond to local pro-inflammatory stimuli to promote local
inflammatory responses and alter local adipocyte function. The peroxisome
proliferator activated receptors PPARg and PPARδ both promote M2
polarization; PPARg plays incompletely defined roles in activation along the
M2 pathway, whereas PPARδ is required for elaboration of the M2
phenotype.
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ATM, adipose tissue macrophage; CCR2, chemokine
receptor 2, IkB, inhibitor of NF-kB; IL, interleukin; IR,
insulin resistance; JNK, Jun kinase; MCP-1, monocyte
chemoattractant protein 1; MSX, metabolic syndrome/
syndrome X; NR, nuclear receptor; PPAR, peroxisome
proliferator activated receptor; TNFa, tumor necrosis
factor a; TNFR, tumor necrosis factor receptor; WAT,
white adipose tissue
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